EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Discovery of highly potent and ALK2/ALK1 selective kinase inhibitors using DNA-encoded chemistry technology

Ravikumar Jimmidi, Diana Monsivais, Hai Minh Ta, Kiran L Sharma iD, Kurt M Bohren iD, Srinivas Chamakuri, Zian Liao iD, Feng Li iD, John M Hakenjos, Jian-Yuan Li, Yuji Mishina iD, Haichun Pan und 12 weitere

Proceedings of the National Academy of Sciences · 19.11.2024 · 121 (47)

DOI: 10.1073/pnas.2413108121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 14.11.2024. Verfasst von Ravikumar Jimmidi und 23 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Discovery, Baylor College of Medicine, Houston, TX 77030. Hauptthemen laut MEDLINE: Activin Receptors, Type I, Protein Kinase Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Burroughs Wellcome Fund (BWF), HHS | NIH (NIH), U.S. Department of Energy (DOE).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Activin receptor type 1 (ACVR1; ALK2) and activin receptor like type 1 (ACVRL1; ALK1) are transforming growth factor beta family receptors that integrate extracellular signals of bone morphogenic proteins (BMPs) and activins into Mothers Against Decapentaplegic homolog 1/5 (SMAD1/SMAD5) signaling complexes. Several activating mutations in ALK2 are implicated in fibrodysplasia ossificans progressiva (FOP), diffuse intrinsic pontine gliomas, and ependymomas. The ALK2 R206H mutation is also present in a subset of endometrial tumors, melanomas, non–small lung cancers, and colorectal cancers, and ALK2 expression is elevated in pancreatic cancer. Using DNA-encoded chemistry technology, we screened 3.94 billion unique compounds from our diverse DNA-encoded chemical libraries (DECLs) against the kinase domain of ALK2. Off-DNA synthesis of DECL hits and biochemical validation revealed nanomolar potent ALK2 inhibitors. Further structure–activity relationship studies yielded center for drug discovery (CDD)-2789, a potent [NanoBRET (NB) cell IC 50 : 0.54 μM] and metabolically stable analog with good pharmacological profile. Crystal structures of ALK2 bound with CDD-2281, CDD-2282, or CDD-2789 show that these inhibitors bind the active site through Van der Waals interactions and solvent-mediated hydrogen bonds. CDD-2789 exhibits high selectivity toward ALK2/ALK1 in KINOMEscan analysis and NB K192 assay. In cell-based studies, ALK2 inhibitors effectively attenuated activin A and BMP-induced Phosphorylated SMAD1/5 activation in fibroblasts from individuals with FOP in a dose-dependent manner. Thus, CDD-2789 is a valuable tool compound for further investigation of the biological functions of ALK2 and ALK1 and the therapeutic potential of specific inhibition of ALK2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Activin Receptors, Type IProtein Kinase InhibitorsHumansActivin Receptors, Type IIDNADrug DiscoverySmall Molecule LibrariesSignal Transduction

Stichwörter der Autor:innen

DELX-ray Crystallographykinase inhibitors

Substanzen

Activin Receptors, Type IProtein Kinase InhibitorsACVR1 protein, humanActivin Receptors, Type IIDNASmall Molecule Libraries

Autor:innen und Institutionen

  • Center for Drug Discovery, Baylor College of Medicine, Houston, TX 77030.
  • Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX 77030.
  • Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030.
  • Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030.
  • Department of Biologic and Materials Science, School of Dentistry, University of Michigan, Ann Arbor, MI 48109.
  • Promega Corporation, Madison, WI 53711.

ORCID-Profile: Kiran L Sharma, Kurt M Bohren, Zian Liao, Feng Li, Yuji Mishina, Xuan Qin, Martin M Matzuk

Förderung

  • Burroughs Wellcome Fund (BWF)
  • HHS | NIH (NIH)
  • U.S. Department of Energy (DOE)
  • NHLBI NIH HHS
  • NICHD NIH HHS
  • NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Jimmidi, R., Monsivais, D., Ta, H. M., Sharma, K. L., Bohren, K. M., Chamakuri, S., Liao, Z., Li, F., Hakenjos, J. M., Li, J. Y., Mishina, Y., Pan, H., Qin, X., Robers, M. B., Sankaran, B., Tan, Z., Tang, S., Vasquez, Y. M., Wilkinson, J., …, & Matzuk, M. M. (2024). Discovery of highly potent and ALK2/ALK1 selective kinase inhibitors using DNA-encoded chemistry technology. Proceedings of the National Academy of Sciences, 121(47). https://doi.org/10.1073/pnas.2413108121

Vancouver

Jimmidi R, Monsivais D, Ta HM, Sharma KL, Bohren KM, Chamakuri S, et al. Discovery of highly potent and ALK2/ALK1 selective kinase inhibitors using DNA-encoded chemistry technology. Proceedings of the National Academy of Sciences. 2024;121(47). doi:10.1073/pnas.2413108121

BibTeX
@article{Jimmidi2024,
  author = {Jimmidi, Ravikumar and Monsivais, Diana and Ta, Hai Minh and Sharma, Kiran L and Bohren, Kurt M and Chamakuri, Srinivas and Liao, Zian and Li, Feng and Hakenjos, John M and Li, Jian-Yuan and Mishina, Yuji and Pan, Haichun and Qin, Xuan and Robers, Matthew B and Sankaran, Banumathi and Tan, Zhi and Tang, Suni and Vasquez, Yasmin M and Wilkinson, Jennifer and Young, Damian W and Palmer, Stephen S and MacKenzie, Kevin R and Kim, Choel and Matzuk, Martin M},
  title = {Discovery of highly potent and ALK2/ALK1 selective kinase inhibitors using DNA-encoded chemistry technology},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  volume = {121},
  number = {47},
  doi = {10.1073/pnas.2413108121}
}
Kostenlos starten →